The National Health Surveillance Agency (Anvisa) identified false advertisements, on social networks and on the internet, about the sale of GLP-1 agonist drugs, popularly known as weight-loss pens, including Mounjaro (tirzepatide).
In a note, the agency warned that false advertisements attract patients by offering cheaper or even free medicines, via the federal government, but after registration.
“Attention: the advertisements are false. Anvisa does not sell any medicine or serve as an intermediary for its sale. The advertisements even simulate the website agency official. The domain gov.anvisa.org does not belong to the agency”, he informed.
In the statement, the entity also highlights that patients should only purchase medicines through regulated pharmacies and drugstores.
“If you find posts like this, report it! And don’t click on related links.”
